Ofatumumab (Arzerra)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Anti-CD20 monoclonal antibody that binds to small and large extracellular loops of the CD20 molecule which is expressed on B-cells. The Fc domain of ofatumumab has been observed in vitro to mediate immune effector functions and B-cell lysis, which is hypothesized to involve complement-dependent cytotoxicity (CDC) and/or antibody-dependent cell mediated cytotoxicity (ADCC).[1][2]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code name: HuMax-CD20
  • Brand name: Arzerra

References

  1. 1.0 1.1 Ofatumumab (Arzerra) package insert
  2. Ofatumumab (Arzerra) package insert (locally hosted backup)
  3. Ofatumumab (Arzerra) patient drug information (Chemocare)
  4. Ofatumumab (Arzerra) patient drug information (UpToDate)